LDS/Medical Tests/Codeine, Urine

Codeine, Urine

Codeine is a naturally occurring opiate alkaloid, obtained from the opium poppy. Today it is largely synthesized by methylation of morphine. Codeine is frequently co-formulated with non-opioid analgesics, such as acetaminophen or aspirin. The typical route of administration is oral (tablets, solution, etc). Codeine is a prodrug and must therefore be metabolized to morphine to produce its therapeutic or toxic effects. A major route of activation is CYP2D6. It is expected that approximately 10% of codeine will be converted to morphine. As such, codeine is a relatively low-potency opioid drug. People with the CYP2D6 poor metabolizer phenotype may experience therapeutic failure and rapid metabolizers may be at risk of accidental overdose. In addition to morphine, the primary metabolites of codeine are norcodeine and several glucuronide conjugates.

The half-life of codeine is 1.2-3.9 hours, which is extended in patients with hepatic or renal impairment.

More than 95% of a typical dose of codeine is eliminated within 48 hours. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention. Codeine can also contribute to the following effects: euphoria, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory collapse, seizure, coma, and possible death.

Codeine and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result indicates only the presence of Codeine and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any positive result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/ml

Toxic level: >200 ng/ml    

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.                 

 

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Immunoassays for opiates are generally sensitive but not specific to codeine. Targeted assays can distinguish between codeine and major metabolites such as morphine, norcodeine, and the glucuronide conjugates. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Urine

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Patients with poor or rapid metabolizer phenotypes for *CYP2D6* should not receive codeine because of the inherent risk of therapeutic failure or toxicity, respectively. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications: 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Crews KR, Gaedigk A, Dunneberger HM, Klein TE, Shen DD, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91(2):321-6.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.